Bumetanide Tablets Rx
Generic Name and Formulations:
Bumetanide 1mg; scored tabs.
Various generic manufacturers
Indications for Bumetanide Tablets:
0.5mg–2mg daily; max 10mg daily. Intermittent dosing optimal.
<18yrs: not recommended.
Anuria. Hepatic coma. Severe electrolyte depletion.
Hepatic cirrhosis. Ascites. Sulfonamide allergy. Progressive renal disease. Gout. Diabetes. Postsympathectomy. Monitor electrolytes, blood, liver function. Potassium supplementation may be needed. Potassium-losing nephropathy. Aldosterone excess. Discontinue if renal dysfunction progresses. Ventricular arrhythmias. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
May increase digitalis, lithium toxicity. Hypokalemia with digitalis, diuretics in CHF. Alcohol, CNS depressants may increase orthostatic hypotension. Avoid probenecid, indomethacin. Ototoxicity may be potentiated with aminoglycosides.
Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, ototoxicity, rash, fluid or electrolyte imbalance, hyperglycemia, hyperuricemia, blood dyscrasias.
Formerly known under the brand name Bumex.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma